Vaccine company Valneva SE (Nasdaq: VALN) (Euronext Paris: VLA) said on Monday that the US Food and Drug Administration (FDA) has granted priority review to the Biologics License Application for its single-shot chikungunya vaccine candidate, VLA1553.

Chikungunya is a mosquito-borne viral disease caused by the chikungunya virus (CHIKV), a Togaviridae virus, transmitted by Aedes mosquitoes. Chikungunya virus often causes sudden large outbreaks with high attack rates, affecting one-third to three-quarters of the population in areas where the virus is circulating. Currently, there are no preventive vaccines or effective treatments available.

VLA1553 has been assigned a Prescription Drug User Fee Act (PDUFA) review goal date at the end of August 2023.